Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tudor-Eliade Ciuleanu

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
The New England Journal of Medicine|May 15, 2024
Perioperative Nivolumab in Resectable Lung CancerTina Cascone, Mark M Awad, Jonathan D Spicer, et al.
The New England Journal of Medicine|June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerDavid P Carbone, Martin Reck, Luis Paz-Ares, et al.
The Lancet. Respiratory Medicine|October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialSantiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2026
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trialHye Ryun Kim, Marc Oliva, Sebastien Salas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
The New England Journal of Medicine|May 15, 2024
Perioperative Nivolumab in Resectable Lung CancerTina Cascone, Mark M Awad, Jonathan D Spicer, et al.
The New England Journal of Medicine|June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerDavid P Carbone, Martin Reck, Luis Paz-Ares, et al.
The Lancet. Respiratory Medicine|October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialSantiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2026
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trialHye Ryun Kim, Marc Oliva, Sebastien Salas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.
Pageof 7